Health Related Quality of Life in NCI-Sponsored Cancer Treatment Trials

Seminars in Oncology Nursing

Volumn 26, Issue 1, 2010, Pages 68-78

  O'Mara, Ann M ^a   Denicoff, Andrea M ^a  

^a NONE

Author keywords

Clinical trials; health related quality of life

Indexed keywords

ARTICLE; BREAST TUMOR; COLORECTAL TUMOR; FEMALE; HUMAN; INFORMATION PROCESSING; LUNG TUMOR; MALE; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NURSING; NURSING ASSESSMENT; NURSING RESEARCH; ONCOLOGY NURSING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; UNITED STATES;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DATA COLLECTION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; NURSING ASSESSMENT; NURSING RESEARCH; ONCOLOGIC NURSING; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; QUALITY OF LIFE; UNITED STATES;

EID: 75749149348     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2009.11.009     Document Type: Article

References (56)

1. O'Mara A., Denicoff A.M., Reeve B.B., et al. A Comparison of Patient-Reported Outcomes (PROs) in National Cancer Institute-Sponsored Treatment Trials in Breast, Colorectal, Lung, and Prostate Cancer During Two Time Periods: 1999-2003 and 2003-2008. [abstr]. Proc Am Soc Clin Oncol 28 suppl (2009) 6618
2. Shapiro A.M., Benedict R.H.B., Schretlen D., et al. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 13 (1999) 348-358
3. Schag C.A., and Heinrich R.L. Development of a comprehensive quality of life measurement tool: CARES. Oncology (Huntingt) 4 (1990) 135-138
4. Center for Epidemiologic Studies. National Institute of Mental Health. Center for Epidemiologic Studies Depression Scale (CES-D) (1971), National Institute of Mental Health, Rockville, MD
5. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
6. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16 (1990) 199-208
7. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
8. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1 (1993) 570-579
9. Schipper H., Clinch J., McMurray A., et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer (FLIC): development and validation. J Clin Oncol 2 (1984) 472-483
10. Zigmond A.S., and Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67 (1983) 361-370
11. Bernhard J., Hürny C., Coates A.S., et al., for the International Breast Cancer Study Group (IBCSG). Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Ann Oncol 8 (1997) 825-835
12. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148 (1992) 1549-1557
13. Veit C.T., and Ware J.E. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol 51 (1983) 730-742
14. McNair D.M., Lorr M., and Droppleman L.F. Manual for the profile of Mood States (1992), Multi-Health Systems Inc., Toronto, ON
15. De Haes J.C.J.M., van Knippenberg F.C.E., and Neijt J.P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62 (1990) 1034-1038
16. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
17. Waterhouse J., and Metcalfe M.C. Development of the sexual adjustment questionnaire. Oncol Nurs Forum 13 (1986) 53-59
18. McCorkle R., and Young K. Development of a symptom distress scale. Cancer Nurs 1 (1978) 373-378
19. Litwin M.S., Hays R.D., Fink A., et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273 (1995) 129-135
20. Ganz P.A., Figlin R.A., Haskell C.M., et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. Cancer 63 (1989) 1271-1278
21. O'Connell M.J. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63 suppl 6 (1989) 1026-1030
22. Lindley C. Outcome assessment: functional status measures and quality of life as therapeutic endpoints in oncology. Top Hosp Pharm Manage 10 (1990) 54-63
23. Aaronson N.K. Quality of life research in cancer clinical trials: a need for common rules and language. Oncology (Williston Park) 4 (1990) 59-70
24. Cella D.F., and Tulsky D.S. Measuring quality of life today: methodological aspects. Oncology (Williston Park) 4 (1990) 29-38 discussion 69
25. Nayfield S.G., Ganz P.A., Moinpour C.M., et al. Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1 (1992) 203-210
26. Moinpour C.M., and Provenzale D. Treatment for colorectal cancer: impact on health-related quality of life. In: Lipscomb J., Gotay C.C., and Snyder C. (Eds). Outcomes Assessment in Cancer (2005), Cambridge University Press, Cambridge, UK 178-200
27. American Cancer Society. CancerFacts and Figures 2009. Breast. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. (Accessed July 30, 2009).
28. Ganz P.A., and Goodwin P.J. Quality of life in breast cancer - what have we learned and where do we go from here?. In: Lipscomb J., Gotay C.C., and Snyder C. (Eds). Outcomes Assessment in Cancer (2005), Cambridge University Press, Cambridge, UK 93-125
29. Fairclough D.L., Fetting J.H., Cella D., et al. Quality of life and quality-adjusted survival for breast cancer patients receiving adjuvant therapy. Qual Life Res 8 (1999) 723-731
30. Peppercorn J., Herndon II J., Kornblith A.B., et al. Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 104 (2005) 1580-1589
31. Land S.R., Kopec J.A., Yothers G., et al. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 86 (2004) 153-164
32. Swain S.M., Land S.R., Ritter M.W., et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113 (2009) 315-320
33. Paskett E., Herndon II J., Donohue K., et al. Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. Cancer 115 (2009) 1109-1120
34. Winer E.P., Berry D.A., Woolf S., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22 (2004) 2061-2068
35. Zhou X., Segreti A., Cella D., et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ metastatic breast cancer: quality of life assessment. Breast Cancer Res Treat 117 (2009) 577-589
36. AmericanCancer Society. Facts and Figures, 2009. Prostate. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. (Accessed July 30, 2009).
37. Litwin D.S., and Talcott J.A. Measuring quality of life in prostate cancer: progress and challenge. In: Lipscomb J., Gotay C.C., and Snyder C. (Eds). Outcomes Assessment in Cancer (2005), Cambridge University Press, Cambridge, UK 126-159
38. Watkins-Bruner D., Scott C., Lawton C., et al. RTOG's first quality of life study-RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33 (1995) 901-906
39. Feigenberg S.J., Lee W.R., Desilvio M.L., et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 62 (2005) 956-964
40. Talcott J.A., Manola J., Clark J.A., et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 21 (2003) 3979-3986
41. Kornblith A.B., Herndon II J.E., Zuckerman E., et al. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 12 (2001) 633-641
42. Ahles T.A., Herndon II J.E., Small E.J., et al. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer 101 (2004) 2202-2208
43. AmericanCancer Society. Facts and Figures, 2009. Colon and Rectum., Available at: http://www.cancer.org/downloads/STT/500809web.pdf. (Accessed July 23, 2009).
44. NationalCancer Institute. Cancer Advances in Focus: Colorectal Cancer. Available at: http://www.cancer.gov/cancertopics/cancer-advances-in-focus/colorectal. (Accessed July 23, 2009).
45. Kabbinavar F.F., Wallace J.F., Holmgren E., et al. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist 13 (2008) 1021-1029
46. Meyerhardt J.A., Sloan J.A., Sargent D.J., et al. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1402-1410
47. Land S.R., Kopec J.A., Cecchini R.S., et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25 (2007) 2205-2211
48. Kopec J.A., Yothers G., Ganz P.A., et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 25 (2007) 424-430
49. AmericanCancer Society. Facts and Figures, 2009. Lung and Bronchus. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. (Accessed July 23, 2009).
50. Earle C.C., and Weeks J.C. The science of quality of life measurement in lung cancer. In: Lipscomb J., Gotay C.C., and Snyder C. (Eds). Outcomes Assessment in Cancer (2005), Cambridge University Press, Cambridge, UK 160-177
51. Schiller J.H., Adak S., Cella D., et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 2114-2122
52. Moinpour C.M., Lyons B., Grevstad P.K., et al. Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res 11 (2002) 115-126
53. Naughton M.J., Herndon II J.E., Shumaker S.A., et al. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual Life Res 11 (2002) 235-248
54. Siddiqui F., Kohl R., Swann S., et al. Gender differences in pretreatment quality of life in a prospective lung cancer trial. J Support Oncol 6 (2008) 33-39
55. Euroqol.org. What is EQ-5D? Available at: http://www.euroqol.org/eq-5d/what-is-eq-5d.html. (Accessed July 26, 2009).
56. Ganz P.A., and Gotay C.C. Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions. J Clin Oncol 25 (2007) 5063-5069